Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085878 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors
A Phase 1 study of Solid Tumor Cancer, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 4
- Study locations
NCT00085878 is a Phase 1 study of Solid Tumor Cancer that has completed, run by GlaxoSmithKline. The registered enrollment target is 25 participants, below the 854-participant average among 10 other Solid Tumor Cancer trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT00085878, a Phase 1 study of Solid Tumor Cancer, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a phase I, open-label, dose-escalation study of SB-485232. Subjects will receive SB-485232 administered as subcutaneous injections daily for 14 days. Dose escalation (enrollment into the next cohort) cannot occur until all three subjects have completed the previous cohort; 5 doses will be tested. An additional dosing regimen has been added to evaluate higher doses given twice weekly for 7 weeks. Therefore, the full evaluation period for each patient will extend out to approximately eleven weeks after the first day of SB-485232 dosing.
Conditions Studied
Interventions
- DRUG SB-485232
Study Locations (4)
California
- GSK Investigational Site - Santa Monica
Indiana
- GSK Investigational Site - Indianapolis
North Carolina
- GSK Investigational Site - Durham
Pennsylvania
- GSK Investigational Site - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2003-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00085878
The ClinicalTrials.gov registry entry for NCT00085878 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 854-participant average among 10 other Solid Tumor Cancer trials with a reported enrollment target (97% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor Cancer appearing as the primary indexed condition, and to 1 intervention - of which SB-485232 is the first listed.
NCT00085878 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Indiana, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00085878 about?
NCT00085878 is a clinical study titled "Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors". This is a phase I, open-label, dose-escalation study of SB-485232. Subjects will receive SB-485232 administered as subcutaneous injections daily for 14 days. Dose escalation (enrollment into the next cohort) cannot occur until all three subjects have completed the previous cohort; 5 doses will be te...
What is the current status of trial NCT00085878?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2003-01.
What conditions does trial NCT00085878 study?
This clinical trial studies the following conditions: Solid Tumor Cancer.
What interventions are being tested in trial NCT00085878?
The interventions under investigation include: SB-485232 (DRUG).
Who is sponsoring clinical trial NCT00085878?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00085878 being conducted?
This trial has 4 study locations across California, Indiana, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
RECRUITING · Phase 1
-
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
RECRUITING · Phase 1
-
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
RECRUITING · Phase 1
-
SB-743921 In Patients With Solid Tumors
COMPLETED · Phase 1
-
A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.